The implementation of G-CSF prophylaxis has not only demonstrated a reduction in the incidence of FN-related dose delays and reductions [34], but also a decrease in infection-related and early mortality [35], although its implication on overall survival and progression-free survival requires further investigation [34,36]. The gene discussed is CSF3; the disease is infection.